Vir Biotechnology, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Vir Biotechnology, Inc.
GSK Ends Pact with Vir For New COVID Treatments
Its Xevudy partner GSK is pulling out but Vir is going to carry on looking for new COVID-19 solutions independently, or with other partners.
Five Challenges Bill Anderson Faces At Bayer
Six weeks after leaving Roche, Bill Anderson is taking the helm at Bayer in one of the most intriguing appointments in the sector for some time.
Deals In 2023: Partnerships And Modest M&A
Mid-sized M&A, collaborations, creative financing, and biotech consolidation will feature in 2023. IPOs and follow-ons play bit-parts.
AstraZeneca's Evusheld Revenue Stream To Dry Up Soon
The revenue boost Evusheld has given AstraZeneca over the past year will grind to a halt now that the FDA, as expected, has pulled approval for the antibody combo on the grounds it is ineffective against most SARS-CoV-2 variants circulating in the US.
- Antisense, Oligonucleotides
- Large Molecule
- Other Names / Subsidiaries
- Humabs BioMed SA
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.